Analysis of the value of test bolus and bolus tracking in diagnosing gastric cancer

Abstract

Background: To explore the clinical value of Test Bolus (TB) scanning technology and Bolus Tracking (BT) technology in the preoperative TNM staging of gastric cancer (GC) patients and the enhanced display of perigastric arteries. Materials and Methods: A retrospective analysis was conducted on the clinical information of 107 gastric cancer patients with complete imaging and pathological diagnostic data (TB group: 30 cases, BT group: 77 cases). Chi-square tests and t-tests were used to compare baseline information between the TB and BT groups. The consistency between the diagnostic results of the TB and BT groups and pathological examination results was analyzed using Kappa tests. Results: There were no statistically significant differences between the TB and BT groups in terms of gender (P=0.499), age (P=0.419), family history of tumors (P=0.979), smoking history (P=0.269), and pain symptoms (P=0.464), while there was a statistically significant difference in alcohol consumption history (P=0.016). The imaging differences between the BT and TB groups were not statistically significant (P>0.05). Except for T staging (P=0.029), there were no statistically significant pathological differences between the BT and TB groups (P>0.05). The consistency of the TB group with pathological results was superior to that of the BT group (Kappa-T: 0.468 vs. 0.439; Kappa-N: 0.301 vs. 0.247; Kappa-M: 0.651 vs. 0.551). Conclusion: TB scanning technology can improve the staging accuracy of GC, achieving better diagnostic performance, but it cannot enhance the display of perigastric arteries.